North America Next-Generation Sequencing Market (2025-2035)

The North America Next-Generation Sequencing (NGS) market is experiencing rapid advancement driven by technological innovations and expanding applications across healthcare and life sciences. This market encompasses a range of sequencing technologies, including whole genome, whole exome, targeted sequencing, and more, accessible via diverse channels. The sector is witnessing increased adoption for personalized medicine, clinical diagnostics, and research, making it crucial in modern healthcare infrastructure.

Get Free Sample PDF:

Bussiness Insights

Latest Market Dynamics

Key Drivers

• Rising demand for personalized medicine: Precision healthcare initiatives are propelling NGS utilization as clinicians rely on comprehensive genomic data for informed treatment. In 2024, Illumina launched new clinical solutions making NGS more accessible for oncology and rare disease diagnostics.
• Declining sequencing costs and faster turnaround times: Technological breakthroughs have reduced sequencing costs substantially while improving data accuracy. Pacific Biosciences' recent partnerships with academic centers have enabled larger population sequencing projects at lower costs.

Key Trends

• Integration of AI and bioinformatics: Advanced analytics and AI are increasingly merged with NGS platforms to accelerate data interpretation. Thermo Fisher Scientific’s Ion Torrent platform now offers integrated analytics powered by machine learning.
• Expansion of liquid biopsy applications: NGS is being adopted for noninvasive cancer diagnostics through liquid biopsies. Guardant Health's North American launch of expanded liquid biopsy panels in 2024 demonstrates this trend.

Key Opportunities

• Growing clinical adoption in oncology: Increased clinical evidence supports NGS-guided cancer therapy selection. Roche’s recent partnership with US healthcare networks to provide comprehensive genomic profiling panels exemplifies this opportunity.
• Agricultural genomics: NGS is being leveraged to enhance crop and livestock traits. In 2024, Agilent Technologies collaborated with agrigenomics firms to develop and validate high-throughput sequencing assays for North American agriculture.

Key Challenges

• Data management, storage, and analysis: The massive data output from NGS requires robust, scalable, and interoperable data infrastructure. QIAGEN faces ongoing challenges in streamlining end-to-end genomic data workflows for clients.
• Regulatory and reimbursement complexities: Changing regulatory landscapes and slow reimbursement pathways impede the integration of NGS into clinical care. Oxford Nanopore continues to navigate these hurdles as it expands clinical diagnostics offerings in North America.

Key Restraints

• High initial investment and operational costs: While costs per genome have fallen, total outlay for NGS infrastructure remains significant. Genapsys has delayed potential market expansion due to capital constraints.
• Limited skilled workforce: Demand for bioinformatics professionals outpaces supply, slowing the adoption rate. Bio-Rad Laboratories has invested in workforce development initiatives, but talent shortage persists.

North America NGS Market YOY Growth (%), 2020-2035

Year-over-year growth in the North America NGS market is expected to peak during 2025–2030, averaging 10.5% annually. As the market matures and broadens its base in diagnostics and research, growth rates will gradually normalize post-2030 to an estimated 7% by 2035, maintaining the region's global leadership in sequencing technologies.

Top Players:

Illumina, Thermo Fisher Scientific, Pacific Biosciences, Oxford Nanopore Technologies, BGI Genomics, Agilent Technologies, QIAGEN, F. Hoffmann-La Roche, PerkinElmer, Eurofins Scientific, Macrogen, Genomatix, Genapsys, GENEWIZ, Bio-Rad Laboratories

Key Recent Developments

• June 2024: Illumina launches its latest NovaSeq X Plus system, doubling data output and reducing whole genome sequencing cost per sample.
• July 2024: Thermo Fisher Scientific partners with major North American cancer centers to deploy advanced Ion Torrent Genexus platforms for clinical oncology.
• August 2024: Roche collaborates with multiple US-based personalized medicine labs to expand comprehensive cancer genomic profiling services.
• September 2024: Agilent Technologies introduces new SureSelect NGS panels tailored for rapid agricultural genomics deployments.
• October 2024: QIAGEN unveils QIAseq Multimodal Panels, streamlining biomarker discovery for clinical and research clients in North America.